Trodelvy Dosage/Direction for Use

Important Use Information: Do NOT substitute TRODELVY for or use with other drugs containing irinotecan or its active metabolite SN-38.
Recommended Dosage: The recommended dosage of TRODELVY is 10 mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles. Continue treatment until disease progression or unacceptable toxicity. Do not administer TRODELVY at doses greater than 10 mg/kg.
Administer TRODELVY as an intravenous infusion only. Do not administer as an intravenous push or bolus.
First infusion: Administer infusion over 3 hours. Observe patients during the infusion and for at least 30 minutes following the initial dose, for signs or symptoms of infusion-related reactions [see Hypersensitivity and Infusion-Related Reactions under Precautions].
Subsequent infusions: Administer infusion over 1 to 2 hours if prior infusions were tolerated. Observe patients during the infusion and for at least 30 minutes after infusion.
Premedication: Prior to each dose of TRODELVY, premedication for prevention of infusion reactions and prevention of chemotherapy-induced nausea and vomiting (CINV) is recommended.
Premedicate with antipyretics, H1 and H2 blockers prior to infusion, and corticosteroids may be used for patients who had prior infusion reactions.
Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK₁ receptor antagonist, as well as other drugs as indicated).
Dose Modifications for Adverse Reactions: Infusion-related Reactions: Slow or interrupt the infusion rate of TRODELVY if the patient develops an infusion-related reaction. Permanently discontinue TRODELVY for life-threatening infusion-related reactions [see Hypersensitivity and Infusion-Related Reactions under Precautions].
Dose Modifications for Adverse Reactions: Withhold or discontinue TRODELVY to manage adverse reactions as described in Table 4. Do not re-escalate the TRODELVY dose after a dose reduction for adverse reactions has been made. (See Table 5.)

Click on icon to see table/diagram/image

Administration: Administer TRODELVY as an intravenous infusion. Protect infusion bag from light. The infusion bag should be covered during administration to the patient until dosing is complete. It is not necessary to cover the infusion tubing or to use light-protective tubing during the infusion.
An infusion pump may be used.
Do not mix TRODELVY, or administer as an infusion, with other medicinal products.
Upon completion of the infusion, flush the intravenous line with 20 mL 0.9% Sodium Chloride Injection, USP.